Not everybody loses the same amount of weight on medications such as Ozempic and Saxenda—treatment indication, dosage, and other factors could play a role, a new study found.

Researchers estimate that expanding access to weight-loss drugs could save over 50,000 lives annually, reducing obesity rates and addressing health inequities. Current drug uptake levels prevent far fewer deaths.

The pharmaceutical industry has seen a tremendous surge in the development of weight loss drugs, particularly GLP-1 receptor agonists such as Ozempic and Wegovy. Click to read.